完全缓解期大 B 细胞淋巴瘤的 CAR-T 细胞输注：国际血液与骨髓移植研究中心分析

CD19 CAR T-cell (CAR-T) therapy is commonly administered to patients with relapsed or refractory large B-cell lymphomas (LBCL), but salvage or bridging therapy can sometimes lead to a complete response (CR) prior to infusion. Limited studies have assessed the outcomes of patients infused in CR. A total of 134 patients with LBCL in CR prior to CAR-T infusion were identified from the CIBMTR registry, with median prior lines of therapy of 3 (range 2-9). At two years post-infusion, the probability of progression-free survival was 43. 5% (95% CI 34. 4-52. 8) and the probability of overall survival was 63.

8% (95% CI 54. 4-72. 6). The cumulative incidence rates of non-relapse mortality and relapse/progression at two years were 9. 2% (95% CI 4. 5-15. 4) and 47. 3% (95% CI 38. 2-56. 6), respectively. The rate of grade 3 or higher cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were 2.

2% and 8. 2%, respectively. In summary, CAR-T in heavily pretreated patients with LBCL who are in CR following two or more lines of prior therapy demonstrate that a subset of patients may remain free of progression at two years.

Additionally, the toxicity profile was impressive with very low rates of grade 3 CRS and ICANS.